3.34Open4.00Pre Close41 Volume217 Open Interest50.00Strike Price12.68KTurnover32.65%IV2.21%PremiumDec 6, 2024Expiry Date1.51Intrinsic Value100Multiplier3DDays to Expiry1.14Extrinsic Value100Contract SizeAmericanOptions Type0.8345Delta0.1531Gamma30.75Leverage Ratio-0.0643Theta0.0039Rho25.66Eff Leverage0.0124Vega
Viking Therapeutics Stock Discussion
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
lets gooooooo
No comment yet